Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,547 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Assessment Only Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

NCT01029704
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001442, Placebo capsules to match EGT0001442
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Birmingham, Alabama • National City, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 27, 2026, 6:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

NCT04123626
View directory record Official record
Conditions
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Interventions
QR-1123, Sham procedure
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Not applicable Interventional

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

NCT02944825
View directory record Official record
Conditions
Urolithiasis, UTI
Interventions
Ciprofloxacin, trimethoprim/sulfamethoxazole, No Intervention
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Foam Tape Allergy a Sticky Situation

NCT06059417
View directory record Official record
Conditions
Medical Adhesive Allergy, Dermatologic Conditions, Dermatologic Lesions
Interventions
2x2 inch piece of 3M microfoam adhesive
Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 27, 2026, 6:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease

NCT02896816
View directory record Official record
Conditions
Parkinson
Interventions
Surface EMG, MRI and PET Scan, Surface EMG
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 27, 2026, 6:02 AM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supporting Baby Behavior Through Pediatric Offices

NCT02438878
View directory record Official record
Conditions
Infant Behavior, Feeding Behavior, Breastfeeding, Pediatric Obesity
Interventions
Baby Behavior
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of 524W91

NCT00002335
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

NCT02867735
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
Interventions
LKA651, Sham Comparator
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 27, 2026, 6:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stress and Pain in People Living With HIV

NCT06784908
View directory record Official record
Conditions
HIV, Depression, Cannabis Use Disorder, Stress, Pain
Interventions
Yale Pain Stress Task (YPST)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 68 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

NCT02601625
View directory record Official record
Conditions
Safety, Pharmacokinetics, Healthy Subjects
Interventions
Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 27, 2026, 6:02 AM EDT
Not yet recruiting Phase 4 Interventional

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

NCT07554417
View directory record Official record
Conditions
GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment
Interventions
Semaglutide, Dietary Counseling, Exercise
Drug · Behavioral
Lead sponsor
William Marsh Rice University
Other
Eligibility
40 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

NCT05363215
View directory record Official record
Conditions
Renal Impairment
Interventions
S-217622
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 27, 2026, 6:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Multi-Reader Multi-Case Pivotal Trial

NCT02692209
View directory record Official record
Conditions
Breast Cancer
Interventions
FFDM Plus DBT, FFDM Alone
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

NCT05462132
View directory record Official record
Conditions
Homocystinuria
Interventions
SYNB1353
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 27, 2026, 6:02 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults

NCT06943378
View directory record Official record
Conditions
Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Interventions
Monoclonal antibody JST-010, Placebo
Biological · Drug
Lead sponsor
Just-Evotec Biologics
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908
View directory record Official record
Conditions
Type II Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 27, 2026, 6:02 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

NCT06852976
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
0.75% MDI-1228_mesylate gel plus Standard of Care, Standard of Care Alone
Drug · Other
Lead sponsor
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 3 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Efprezimod alfa, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 27, 2026, 6:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-05161704 In Healthy Volunteers

NCT01183715
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05161704 or placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 27, 2026, 6:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

NCT05262023
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
DNL593, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 27, 2026, 6:02 AM EDT